Kyprolis and Rash erythematous - a phase IV clinical study of FDA data

Summary:

Rash erythematous is reported as a side effect among people who take Kyprolis (carfilzomib), especially for people who are male, 60+ old, also take Revlimid, and have Chronic inflammatory demyelinating polyradiculoneuropathy.

The phase IV clinical study analyzes which people have Rash erythematous when taking Kyprolis. It is created by eHealthMe based on reports of 15,068 people who have side effects when taking Kyprolis from the FDA, and is updated regularly.

What is Kyprolis?

Kyprolis has active ingredients of carfilzomib. It is often used in multiple myeloma. eHealthMe is studying from 15,080 Kyprolis users. Check the latest studies of Kyprolis.

What is Rash erythematous?

Rash erythematous (redness of the skin) is found to be associated with 1,810 drugs and 1,902 conditions by eHealthMe. Check the latest studies of Rash erythematous.

On Jul, 10, 2026

15,068 people reported to have side effects when taking Kyprolis.
Among them, 15 people (0.1%) have Rash erythematous.

Among these 15 people:

What is the gender of people who have Rash erythematous when taking Kyprolis? *

female: 46.67 %
male: 53.33 %

What is the age of people who have Rash erythematous when taking Kyprolis? *

What are other drugs people take besides Kyprolis? *

What are other side effects people have besides Rash erythematous? *

Pain: 3 people, 20.00%
Rash Pruritic (redness with itching): 3 people, 20.00%
Hepatitis (inflammation of the liver): 2 people, 13.33%
Joint Pain: 2 people, 13.33%
Joint Range Of Motion Decreased (disease of joint movement): 2 people, 13.33%
Neuropathy Peripheral (surface nerve damage): 2 people, 13.33%
Pain In Extremity: 2 people, 13.33%
Paraparesis (partial paralysis of the lower limbs): 2 people, 13.33%
Pneumonia: 2 people, 13.33%
Activities Of Daily Living Impaired: 2 people, 13.33%

What are the existing conditions these people have? *

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Kyprolis and have Rash erythematous?

- Check whether Rash erythematous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kyprolis:

Kyprolis (15,080 reports)

Browse all side effects of Kyprolis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash erythematous:

Rash erythematous (1,810 drugs)

Browse all the conditions that are associated with Rash erythematous:

Rash erythematous (1,902 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib (the active ingredients of Kyprolis) and Kyprolis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.